Spots Global Cancer Trial Database for cd22 positive
Every month we try and update this database with for cd22 positive cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | NCT02311998 | B Acute Lymphob... Blast Phase Chr... Blasts More Tha... CD22 Positive Philadelphia Ch... Recurrent Chron... Refractory Chro... | Bosutinib Inotuzumab Ozog... | 18 Years - | M.D. Anderson Cancer Center | |
Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML | NCT02311998 | B Acute Lymphob... Blast Phase Chr... Blasts More Tha... CD22 Positive Philadelphia Ch... Recurrent Chron... Refractory Chro... | Bosutinib Inotuzumab Ozog... | 18 Years - | M.D. Anderson Cancer Center | |
ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia | NCT03698552 | Blasts 5 Percen... CD22 Positive Philadelphia Ch... Recurrent B Acu... Refractory B Ac... | ADCT-602 | 18 Years - | M.D. Anderson Cancer Center | |
Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leukemia | NCT03094611 | CD22 Positive Recurrent Acute... Refractory Acut... | Inotuzumab Ozog... | 12 Years - | M.D. Anderson Cancer Center | |
Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma | NCT01535989 | B-cell Lymphoma... | Inotuzumab Ozog... Temsirolimus | 18 Years - | Oncology Institute of Southern Switzerland |